Gemcitabine and Nab-Paclitaxel Combined With the Oral Irreversible ErbB Family Blocker Afatinib in Patients With Metastatic Pancreatic Cancer: A Phase Ib Trial
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Afatinib (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms AFFECT
- 01 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
- 01 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 01 Dec 2016 New trial record